Please assess the completion status of the following clinical trial:

Trial Title: EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed SARS-CoV-2 infection within 5 days prior to randomization~* Initial onset of COVID-19 signs/symptoms within 5 days prior to the day of randomization and at least 1 of the specified COVID-19 signs/symptoms present on the day of randomization~* Fertile participants must agree to use a highly effective method of contraception~* Has at least 1 characteristic or underlying medical condition associated with an increased risk of developing severe illness from COVID-19~Exclusion Criteria:~* History of or need for hospitalization for the medical treatment of COVID-19~* Prior to current disease episode, any confirmed SARS-CoV-2 infection~* Known medical history of active liver disease~* Receiving dialysis or have known moderate to severe renal impairment~* Known human immunodeficiency virus (HIV) infection with a viral load greater than 400 copies/mL or taking prohibited medications for HIV treatment~* Suspected or confirmed concurrent active systemic infection other than COVID-19~* History of hypersensitivity or other contraindication to any of the components of the study intervention~* Current or expected use of any medications or substances that are highly dependent on CYP3A4 for clearance or are strong inducers of CYP3A4~* Has received or is expected to receive convalescent COVID-19 plasma~* Has received or is expected to receive any dose of a SARS-CoV-2 vaccine before the Day 34 visit~* Participating in another interventional clinical study with an investigational compound or device, including those for COVID-19 through the long-term follow-up visit~* Known prior participation in this trial or other trial involving PF-07321332~* Oxygen saturation of \<92% on room air, or on their standard home oxygen supplementation for those who regularly receive chronic supplementary oxygen for an underlying lung condition~* Females who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-07321332/ritonavir (Type: EXPERIMENTAL): Orally administered PF-07321332+ritonavir
- Placebo (Type: PLACEBO_COMPARATOR): Orally administered placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).